{
  "source": "PA-Notification-Inqovi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1343-5\nProgram Prior Authorization/Notification\nMedications Inqovi® (decitabine and cedazuridine) tablet\nP&T Approval Date 12/2020, 2/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nInqovi is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a\ncytidine deaminase inhibitor, indicated for the treatment of adult patients with myelodysplastic\nsyndromes (MDS), including previously treated and untreated, de novo and secondary MDS with\nthe following French-American-British subtypes (refractory anemia, refractory anemia with\nringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia\n[CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring\nSystem (IPSS) groups.\nThe National Cancer Comprehensive Network (NCCN) notes that Inqovi could be considered as\na substitution for intravenous decitabine in patients with IPSS intermediate-1 and above.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Inqovi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Myelodysplastic Syndrome (MDS)\n1. Initial Authorization\na. Inqovi will be approved based on both of the following:\n(1) Diagnosis of myelodysplastic syndrome [e.g., previously treated and untreated, de\nnovo and secondary MDS with the following French American-British ",
    "ill be approved based on both of the following:\n(1) Diagnosis of myelodysplastic syndrome [e.g., previously treated and untreated, de\nnovo and secondary MDS with the following French American-British subtypes\n(refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia\n© 2025 UnitedHealthcare Services, Inc.\n1\nwith excess blasts, and chronic myelomonocytic leukemia (CMML)]\n-AND-\n(2) Patient is intermediate-1, intermediate-2, or high-risk per the International\nPrognostic Scoring System (IPSS)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Inqovi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Inqovi therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Inqovi [package insert]. Princeton, NJ: Taiho Oncology, Inc.; March 2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed December 20, 2024.\nProgram Prior Authorization/Notification – Inqovi® (decitabine and\ncedazuridine)\nChange Control\n12/2020 New program.\n2/2022 Annual review. Updated background and references with no c",
    "ecember 20, 2024.\nProgram Prior Authorization/Notification – Inqovi® (decitabine and\ncedazuridine)\nChange Control\n12/2020 New program.\n2/2022 Annual review. Updated background and references with no changes to\nthe clinical criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2\n2/2023 Annual review with no changes to coverage criteria. Added state\nmandate footnote and updated references.\n2/2024 Annual review with no changes to coverage criteria. Updated\nreferences.\n2/2025 Annual review. Removed CMML as it would fall under MDS. Updated\nreferences.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}